Skip to main content
SpringerLink
Log in

Reproductive Issues in BRCA Mutation Carriers

  • Chapter
Breast Cancer, Fertility Preservation and Reproduction

Abstract

One of the most significant risk factors for developing early onset breast cancer is the presence of a BRCA1/2 mutation. The presence of a BRCA1/2 mutation confers a 40–90 % lifetime risk of developing breast cancer and up to a 60 % lifetime risk of developing ovarian cancer. BRCA1/2 plays an important role on the causal pathway for developing breast cancer and has a significant impact on the biological and clinical characteristics of BRCA1/2-associated breast cancer. The presence of a BRCA1/2 mutation has far-reaching impact on the full spectrum of reproductive issues, including the impact of risk-reducing salpingo-oophorectomy both on fertility and premature menopause. The presence of a BRCA1/2 mutation compounds the already complex and multifactorial challenges that exist when managing a young woman with breast cancer – the challenges range from medical (oncological, gynecological, surgical) to psychosocial and ethical; thus, a multidisciplinary approach is mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389–99.

    Google Scholar 

  2. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer. 2010;10(5):353–61.

    CAS  PubMed  Google Scholar 

  3. Cox A, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007;39(3):352–8.

    CAS  PubMed  Google Scholar 

  4. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43.

    CAS  PubMed  Google Scholar 

  5. Levy-Lahad E, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997;60(5):1059–67.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Ford D, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Lancet. 1994;343(8899):692–5.

    CAS  Google Scholar 

  8. King MC, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6.

    CAS  PubMed  Google Scholar 

  9. Mavaddat N, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22.

    CAS  PubMed  Google Scholar 

  10. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res. 2005;3(10):531–9.

    CAS  PubMed  Google Scholar 

  11. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7(2):263–72.

    CAS  PubMed  Google Scholar 

  12. Golshan M, et al. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg. 2006;192(1):58–62.

    CAS  PubMed  Google Scholar 

  13. Peto J, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943–9.

    CAS  PubMed  Google Scholar 

  14. Neuhausen S, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996;13(1):126–8.

    CAS  PubMed  Google Scholar 

  15. Offit K, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996;347(9016):1643–5.

    CAS  PubMed  Google Scholar 

  16. Struewing JP, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401–8.

    CAS  PubMed  Google Scholar 

  17. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Kauff ND, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–15.

    PubMed  Google Scholar 

  19. Rebbeck TR, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–22.

    PubMed  Google Scholar 

  20. Rebbeck TR, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475–9.

    CAS  PubMed  Google Scholar 

  21. Eisen A, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491–6.

    PubMed  Google Scholar 

  22. Genetic/familial high risk assessment: breast & ovarian. National Comprehensive Cancer Network.

    Google Scholar 

  23. Robson M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999;91(24):2112–7.

    CAS  PubMed  Google Scholar 

  24. Warner E, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.

    CAS  PubMed  Google Scholar 

  25. Veronesi A, et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer. 2005;5:70.

    PubMed Central  PubMed  Google Scholar 

  26. Lakhani SR, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.

    CAS  PubMed  Google Scholar 

  27. Atchley DP, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–8.

    PubMed  Google Scholar 

  28. Rennert G, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(2):115–23.

    CAS  PubMed  Google Scholar 

  29. Huzarski T, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31(26):3191–6.

    PubMed  Google Scholar 

  30. Robson ME, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6(1):R8–17.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Goodwin PJ, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30(1):19–26.

    PubMed  Google Scholar 

  32. Bayraktar S, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130(1):145–53.

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Lee E, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29(33):4373–80.

    PubMed Central  PubMed  Google Scholar 

  34. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst. 1998;90(13):978–85.

    CAS  PubMed  Google Scholar 

  35. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    CAS  PubMed  Google Scholar 

  36. Tutt AN, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol. 2005;70:139–48.

    CAS  PubMed  Google Scholar 

  37. Tassone P, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88(8):1285–91.

    PubMed Central  CAS  PubMed  Google Scholar 

  38. Quinn JE, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63(19):6221–8.

    CAS  PubMed  Google Scholar 

  39. Kennedy RD, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96(22):1659–68.

    CAS  PubMed  Google Scholar 

  40. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 2006;5(2):135–42.

    CAS  PubMed  Google Scholar 

  41. Kriege M, et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(23):3764–71.

    PubMed  Google Scholar 

  42. Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with “BRCAness”: a review. Oncologist. 2013;18(8):909–16.

    PubMed Central  CAS  PubMed  Google Scholar 

  43. Bayraktar S, Gluck S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat. 2013;135(2):355–66.

    Google Scholar 

  44. Byrski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375–9.

    CAS  PubMed  Google Scholar 

  45. Byrski T, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2014;14(4):R110.

    Google Scholar 

  46. Silver DP, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145–53.

    PubMed Central  CAS  PubMed  Google Scholar 

  47. Wysocki PJ, et al. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit. 2008;14(7):SC7–10.

    CAS  PubMed  Google Scholar 

  48. Byrski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108(2):289–96.

    CAS  PubMed  Google Scholar 

  49. Kriege M, et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 2012;118(4):899–907.

    CAS  PubMed  Google Scholar 

  50. Anders CK, et al. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16(19):4702–10.

    PubMed Central  CAS  PubMed  Google Scholar 

  51. Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    CAS  PubMed  Google Scholar 

  52. Tutt A, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44.

    CAS  PubMed  Google Scholar 

  53. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091.

    PubMed  Google Scholar 

  54. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;(4):CD007245.

    Google Scholar 

  55. Shi Q, et al. The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen. Eur J Gynaecol Oncol. 2014;35(5):492–8.

    Google Scholar 

  56. Fu Y, Zhuang Z. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol. 2014;7(10):6419–29.

    PubMed Central  PubMed  Google Scholar 

  57. Trinh XB, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90(1):17–22.

    CAS  PubMed  Google Scholar 

  58. Lyytinen HK, et al. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer. 2010;126(2):483–9.

    CAS  PubMed  Google Scholar 

  59. Kwon JS, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121(1):14–24.

    PubMed  Google Scholar 

  60. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol. 2014;4:21.

    PubMed Central  PubMed  Google Scholar 

  61. Charlton BM, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. BMJ. 2014;349:g6356.

    PubMed Central  PubMed  Google Scholar 

  62. Bernholtz S, et al. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Breast Cancer Res Treat. 2011;129(2):557–63.

    CAS  PubMed  Google Scholar 

  63. Cibula D, et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11(8):1197–207.

    CAS  PubMed  Google Scholar 

  64. Jernstrom H, et al. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer. 2005;41(15):2312–20.

    PubMed  Google Scholar 

  65. Kotsopoulos J, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014;143(3):579–86.

    CAS  PubMed  Google Scholar 

  66. Gadducci A, et al. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol. 2010;26(8):568–77.

    PubMed  Google Scholar 

  67. Narod SA, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94(23):1773–9.

    CAS  PubMed  Google Scholar 

  68. Iodice S, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275–84.

    CAS  PubMed  Google Scholar 

  69. Moorman PG, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–98.

    CAS  PubMed  Google Scholar 

  70. Grenader T, et al. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast. 2005;14(4):264–8.

    PubMed  Google Scholar 

  71. Lee E, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3170–8.

    CAS  PubMed  Google Scholar 

  72. Haile RW, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1863–70.

    CAS  PubMed  Google Scholar 

  73. Milne RL, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(2):350–6.

    CAS  PubMed  Google Scholar 

  74. Althuis MD, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003;14(2):151–60.

    PubMed  Google Scholar 

  75. Tavani A, et al. Risk factors for breast cancer in women under 40 years. Eur J Cancer. 1999;35(9):1361–7.

    CAS  PubMed  Google Scholar 

  76. Kotsopoulos J, et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005;16(6):667–74.

    PubMed  Google Scholar 

  77. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187–95.

    Google Scholar 

  78. Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat. 2002;72(2):107–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  79. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2002;2(2):113–23.

    PubMed  Google Scholar 

  80. Cullinane CA, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005;117(6):988–91.

    CAS  PubMed  Google Scholar 

  81. Andrieu N, et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006;98(8):535–44.

    PubMed Central  PubMed  Google Scholar 

  82. Antoniou AC, et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2006;8(6):R72.

    PubMed Central  PubMed  Google Scholar 

  83. Milne RL, et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010;119(1):221–32.

    CAS  PubMed  Google Scholar 

  84. Pan H, et al. Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies. Cancer Epidemiol. 2014;38(1):1–8.

    PubMed  Google Scholar 

  85. Lecarpentier J, et al. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Res. 2012;14(4):R99.

    PubMed Central  PubMed  Google Scholar 

  86. Jernstrom H, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2004;96(14):1094–8.

    CAS  PubMed  Google Scholar 

  87. Kotsopoulos J, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42.

    PubMed Central  CAS  PubMed  Google Scholar 

  88. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl). 2012;8(5):543–55.

    CAS  Google Scholar 

  89. Valentini A, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914–9.

    PubMed Central  PubMed  Google Scholar 

  90. Tea MK, et al. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age. Maturitas. 2013;75(2):148–51.

    CAS  PubMed  Google Scholar 

  91. Pal T, et al. Fertility in women with BRCA mutations: a case-control study. Fertil Steril. 2010;93(6):1805–8.

    CAS  PubMed  Google Scholar 

  92. Finch A, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8.

    CAS  PubMed  Google Scholar 

  93. Lin WT, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  94. Oktay K, et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Wang ET, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–8.

    CAS  PubMed  Google Scholar 

  96. Kotsopoulos J, et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control. 2008;19(10):1111–9.

    PubMed  Google Scholar 

  97. Moslehi R, et al. Impact of BRCA mutations on female fertility and offspring sex ratio. Am J Hum Biol. 2010;22(2):201–5.

    PubMed Central  PubMed  Google Scholar 

  98. Oktay K, et al. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J Clin Oncol. 2014;32(10):1093–4.

    PubMed  Google Scholar 

  99. French JD, et al. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines. Genes Chromosomes Cancer. 2006;45(3):277–89.

    CAS  PubMed  Google Scholar 

  100. McPherson JP, et al. A role for Brca1 in chromosome end maintenance. Hum Mol Genet. 2006;15(6):831–8.

    CAS  PubMed  Google Scholar 

  101. Bau DT, et al. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res. 2004;64(14):5013–9.

    CAS  PubMed  Google Scholar 

  102. Zhong Q, et al. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem. 2002;277(32):28641–7.

    CAS  PubMed  Google Scholar 

  103. Bae I, et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004;64(21):7893–909.

    CAS  PubMed  Google Scholar 

  104. Titus S, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.

    PubMed  Google Scholar 

  105. Giscard d’Estaing S, et al. Upregulation of the BRCA1 gene in human germ cells and in preimplantation embryos. Fertil Steril. 2005;84(3):785–8.

    PubMed  Google Scholar 

  106. Gleicher N, Weghofer A, Barad DH. Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reprod Biomed Online. 2010;20(6):768–75.

    CAS  PubMed  Google Scholar 

  107. Brandao RD, et al. FMR1 low sub-genotype does not rescue BRCA1/2-mutated human embryos and does not explain primary ovarian insufficiency among BRCA1/2-carriers. Hum Reprod. 2013;28(8):2308–11.

    CAS  PubMed  Google Scholar 

  108. Prostaglandins and abortion. I. intramuscular administration of 15-methyl prostaglandin F2alpha for induction of abortion in weeks 10 to 20 of pregnancy. World Health Organization Task Force on the Use of Prostaglandins for the Regulation of Fertility. Am J Obstet Gynecol. 1977;129(6):593–6.

    Google Scholar 

  109. Fortuno C, Labarta E. Genetics of primary ovarian insufficiency: a review. J Assist Reprod Genet. 2014;31(12):1573–85.

    PubMed  Google Scholar 

  110. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Womens Health. 2014;6:235–43.

    PubMed Central  PubMed  Google Scholar 

  111. Collins IM, et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol. 2013;31(31):3920–5.

    PubMed  Google Scholar 

  112. Rzepka-Gorska I, et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100(1):59–63.

    CAS  PubMed  Google Scholar 

  113. Fusek M, Lin XL, Tang J. Enzymic properties of thermopsin. J Biol Chem. 1990;265(3):1496–501.

    CAS  PubMed  Google Scholar 

  114. Roness H, Kalich-Philosoph L, Meirow D. Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents. Hum Reprod Update. 2014;20(5):759–74.

    PubMed  Google Scholar 

  115. Michaelson-Cohen R, et al. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233–7.

    PubMed  Google Scholar 

  116. Meirow D, Eldar-Geva T, Manela D, Brenghausen M, Shapira M, Raanani H. BRCA mutation carriers do not show reduced ovarian reserve as demonstrated by IVF treatments outcome, in ASRM. Fertil Steril: Honolulu; 2014.

    Google Scholar 

  117. Smith KR, et al. Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci. 2012;279(1732):1389–95.

    PubMed Central  CAS  PubMed  Google Scholar 

  118. Smith KR, Hanson HA, Hollingshaus MS. BRCA1 and BRCA2 mutations and female fertility. Curr Opin Obstet Gynecol. 2013;25(3):207–13.

    PubMed Central  PubMed  Google Scholar 

  119. Broer SL, et al. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701.

    CAS  PubMed  Google Scholar 

  120. Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol. 2010;53(4):753–62.

    PubMed Central  PubMed  Google Scholar 

  121. Meirow D, et al. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–39.

    PubMed  Google Scholar 

  122. Adams E, Hill E, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists’ current knowledge, practice and attitudes. Br J Cancer. 2013;108(8):1602–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  123. Munster PN. Fertility preservation and breast cancer: a complex problem. Oncology (Williston Park). 2013;27(6):533–9.

    Google Scholar 

  124. Moffat R, Guth U. Preserving fertility in patients undergoing treatment for breast cancer: current perspectives. Breast Cancer (Dove Med Press). 2014;6:93–101.

    Google Scholar 

  125. Meirow D, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril. 2014;102(2):488–95 e3.

    CAS  PubMed  Google Scholar 

  126. Basille C, et al. Preimplantation genetic diagnosis: state of the art. Eur J Obstet Gynecol Reprod Biol. 2009;145(1):9–13.

    CAS  PubMed  Google Scholar 

  127. Sagi M, et al. Preimplantation genetic diagnosis for BRCA1/2–a novel clinical experience. Prenat Diagn. 2009;29(5):508–13.

    CAS  PubMed  Google Scholar 

  128. Derks-Smeets IA, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treat. 2014;145(3):673–81.

    PubMed  Google Scholar 

  129. Ramon YCT, et al. Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain. Fam Cancer. 2012;11(2):175–9.

    Google Scholar 

  130. Hurley K, et al. Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences. Cancer. 2012;118(24):6270–7.

    PubMed  Google Scholar 

  131. Berliner JL, Fay AM, Practice Issues Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk Counseling Special Interest Group. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16(3):241–60.

    PubMed  Google Scholar 

  132. Staton AD, et al. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer. 2008;7(2):179–86.

    PubMed  Google Scholar 

  133. Menon U, et al. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod. 2007;22(6):1573–7.

    CAS  PubMed  Google Scholar 

  134. Smith KR, et al. Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004;13(5):733–40.

    PubMed  Google Scholar 

  135. Quinn GP, et al. Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer. Fam Cancer. 2009;8(4):441–9.

    PubMed  Google Scholar 

  136. Ormondroyd E, et al. Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet. 2012;20(1):4–10.

    PubMed Central  PubMed  Google Scholar 

  137. Meirow D, Ra’anani H, Biderman H. Ovarian tissue cryopreservation and transplantation: a realistic, effective technology for fertility preservation. Methods Mol Biol. 2014;1154:455–73.

    PubMed  Google Scholar 

  138. Gamzatova Z, et al. Autotransplantation of cryopreserved ovarian tissue–effective method of fertility preservation in cancer patients. Gynecol Endocrinol. 2014;30 Suppl 1:43–7.

    PubMed  Google Scholar 

  139. Meirow D, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod. 2008;23(5):1007–13.

    PubMed  Google Scholar 

  140. Dolmans MM, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14.

    CAS  PubMed  Google Scholar 

  141. Rosendahl M, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril. 2010;94(6):2186–90.

    PubMed  Google Scholar 

  142. Rosendahl M, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158–61.

    PubMed  Google Scholar 

  143. Sanchez-Serrano M, et al. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod. 2009;24(9):2238–43.

    PubMed  Google Scholar 

  144. Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11–24.

    PubMed Central  PubMed  Google Scholar 

  145. Bastings L, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update. 2013;19(5):483–506.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Service for Young Women, Breast Oncology Institute, Tel Hashomer, 52621, Israel

    Shani Paluch-Shimon

  2. Division of Oncology, Sheba Medical Centre, Tel Hashomer, 52621, Israel

    Shani Paluch-Shimon

  3. Fertility Preservation, IVF Unit, Department of Obstetrics & Gynaecology, Sheba Medical Centre, Tel Hashomer, 52621, Israel

    Dror Meirow

  4. IVF Unit, Department of Obstetrics and Gynecology, The Hadassah University Hospital, Ein Kerem, Jerusalem, Israel

    Jordana Hyman

Authors
  1. Shani Paluch-Shimon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dror Meirow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jordana Hyman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shani Paluch-Shimon .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Torino School of Medicine, Mauriziano Umberto I Hospital, Torino, Italy

    Nicoletta Biglia

  2. Fertility and Procreation Unit, Istituto Europeo di Oncologia, Milano, Italy

    Fedro Alessandro Peccatori

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Paluch-Shimon, S., Meirow, D., Hyman, J. (2015). Reproductive Issues in BRCA Mutation Carriers. In: Biglia, N., Peccatori, F. (eds) Breast Cancer, Fertility Preservation and Reproduction. Springer, Cham. https://doi.org/10.1007/978-3-319-17278-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17278-1_7

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17277-4

  • Online ISBN: 978-3-319-17278-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation